Effect of Cetuximab and <i>EGFR</i> Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type <i>EGFR</i> and Use of <i>KRAS</i> as a Possible Biomarker for Treatment Responsiveness

Naomi Miyake(Tottori University), Akira Yamasaki(Kawasaki Medical School)
Yonago acta medica
January 1, 2019
Cited by 5


Related Papers